Los medicamentos genéricos, entre la propiedad privada y la salud pública

  1. Juberías Sánchez, Antonio
unter der Leitung von:
  1. José María Caballero Lozano Doktorvater/Doktormutter

Universität der Verteidigung: Universidad de Burgos

Fecha de defensa: 09 von November von 2012

Gericht:
  1. Carlos Vattier Fuenzalida Präsident/in
  2. Elena Vicente Domingo Sekretär/in
  3. José Miguel Rodríguez Tapia Vocal
  4. Elena de La Cuesta Elósegui Vocal
  5. Carlos Rogel Vide Vocal

Art: Dissertation

Teseo: 348844 DIALNET lock_openRIUBU editor

Zusammenfassung

Health authorities will seek the full availability of safe, effective, and quality drugs care for diseases and conditions that affect the community. The high costs associated with the development and commercialization of new molecules, are the source of high drug prices, which increase drug costs borne by society. The existence of generic drug implies cheaper availability but with equal efficacy that innovators, allowing them to act as an effective tool to control pharmaceutical cost supported by national health systems. The generic marketing advantage of the effort and technology used by innovative medicines, this is the key for your lower price. The marketing of generic drugs, show a number of implications for institutions of a private law as property, patent, design, trademark or liability for defects in the product, which will determine the introduction and availability of generics in the pharmaceutical market.